Kadar mRNA Hypoxia Inducible Factor Alpha Plasma Darah Pasien Kanker Ovarium Tipe Mucinous Dan Serous

Siti Nur Chasanah, Teguh Aryandono, Sofia Mubarika Haryana


Proses karsinogenesis pada kanker ovarium melibatkan regulasi tingkat molekular, salah satunya adalah mRNA. Beberapa penelitian sebelumnya menyebutkan bahwa disregulasi mRNA HIF1A terjadi pada berbagai kanker. Penelitian melaporkan adanya peningkatan ekspresi mRNA HIF1A pada kanker ovarium. Kanker sering berada dalam kondisi hipoksia, mRNA HIF1A merupakan regulator gen pada kondisi hipoksia. HIF1A terlibat dalam berbagai hallmark kanker. Berdasarkan hal tersebut, penelitian ini dilakukan untuk mengetahui apakah terdapat perbedaan ekspresi mRNA HIF1A pada plasma penderita kanker ovarium tipe mucinous dan serous. Sampel plasma diambil dari pasien kanker ovarium di RSUP Dr. Sardjito, tipe mucinous sebanyak 9 sampel dan tipe serous sebanyak 9 sampel. Total RNA diisolasi dari sampel plasma darah pasien kanker ovarium dengan menggunakan miRCURY RNA isolation Kit-Biofluid. Kuantifikasi mRNA HIF1A dilakukan One-step qRT-PCR dengan kit KAPA TM SYBR®. Hasil qRT-PCR dianalisis dengan menggunakan Biorad CFX Manager TM Software. Hasil analisis menunjukkan bahwa terdapat perbedaan ekspresi mRNA HIF1A pada tipe serous dibandingkan dengan tipe mucinous (p value =0,018). Ekspresi mRNA HIF1A pada tipe serous meningkat 5,62 kali lipat dibandingkan dengan tipe mucinous. Penelitian ini telah berhasil membuktikan bahwa mRNA HIF1A lebih tinggi pada kanker ovarium tipe serous. 


Plasma, mRNA HIF1A, Serous, Mucinous



Full Text:



Ahmedin, J. Siegel, R. Xu, J. and Ward, E. 2018. Cancer Statistics. CA Cancer Clin. 60:277–300.

Ferlay, J. Soerjomataram, I. Ervik, M. Dikshit, R. Eser, S.C. Mathers, M. Rebelo, M. Parkin, D.M. Forman, D. and Bray, F. 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2018. Globocan. ARC Cancer Base. Diakses dari http://www.iarc.fr/en/publications/eresources /cancerbases/.

GLOBOCAN, 2012. Estimated cancer incidence, mortality, and prevalence worldwide in 2018. Diakses dari http://globocan.iarc.fr/Pages/online.aspx

Liu, B.Y. 2012a. microRNA 155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep. 1-6.

American Cancer Society. Global Cancer Fact & Figures (2nd Edition). 2011. American Cancer Society. Atlanta GA. USA.

Nguyen, L. Cardenas, G. Segundo, J. Gordon, P. Curtin, C. Momeni, M. Chuang, L. and Fishman, D. 2013. Biomarkers for early detection of ovarian cancer. Women’s Health. 9(2):171-187.

Babar, I.A.J. Czocor, A. Steinmetz, J. B. Weidhaas, P.M. Glazer, and Slack, F.J. 2011. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology & Therapy. USA. 12(10):908–914.

Conde, E. Laura, A. Ignacio, B.S. David, S.M. Elia, A.F. Bele´n, P. Edurne, R. Ana, S. Carlos, J. Angel, O. Manuel, L.C. Luis-del, P. Manuel, O. de, L. Fernando, L. Rafael, S. Jose, A.S. Tomero, and Marı´a L.G.B. 2012. Hypoxia inducible factor 1-alpha (HIF-1 Alpha) is induced during reperfusion after renal ischemia and is critical for proximal tubule cell survival. Plos One. 7(3):33258.

Becker, C. A. Hammerle-Fickinger, I. Riedmaier, M.W. Pfaffl. 2010. mRNA and microRNA quality control for RT-qPCR analysis. Methods 50: 237-243.

George, G.P. and Mittal, R.D. 2010. microRNAs: Potential biomarker in cancer. Clin Biochem. 1:4-14.

Ren, Y. Gao, J. Liu, J.Q. Wang, X.W. Gu, J. Huang, H. Gong, Y. and Li, Z. 2012. Differential signature of fecal microRNAs in patients with pancreatic cancer.

Wang and Chen. 2014. Circulating miRNAs in cancer: from detection to Therapy. Journal of Hematology & Oncology. 7:86.

Falcone, G. Felsani, A. and D’Agnano, I. 2015. Signaling by exosomal microRNAs in cancer. Journal of Experimental & Clinical Cancer Research. 34(32):1-10.

Nakamura, K. Sawada, K. Yoshimura, A. Kinose, Y. Nakatsuka, E. and Kimura, T. 2016. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Molecular Cancer. 15(48):1-10.

Cheng, G. 2015. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Del Rev. (81):75–93.

Zheng, S.R. Gui, L.G. Wei, Z. Guan, L.H. Xiao, Q. Jin, Z. Qi, D.H. Jie, Y. and Xiao, H.Z. 2012. Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol Rep. 27:1149-1155.

Li, C. Nie, H. Wang, M. Sui, L. Li, J. Yui, Y. Yan, M. Qu, Q. Zhu, Z. and Liu, B. 2012. microRNA 155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 27:1960-1966.

Qin, W. Ren, Q. Liu, T. and Huang, Y. 2013. MicroRNA-155 is a novel uppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Letters. 587(9):1434-1439.

Davis, B.N., Hilyard, A.C., Lagna, G., Hata, A., 2008. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 454:56-61.

Melo, S.A., Moutinho, C., Ropero, S., Calin, G.A., Rossi, S., Spizzo, R., Fernandez, A.F., Davalos, V., Villanueva, A., Montoya, G., Yamamoto, H., Schwartz Jr., S., Esteller, M., 2010. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell. 18:303-315.

Newman, M.A., Hammond, S.M., 2010. Emerging paradigms of regulated microRNA processing. Genes Dev. 24: 1086-1092.

Warner, D.R., Bhattacherjee, V., Yin, X., Singh, S., Mukhopadhyay, P., Pisano, M.M., Greene, R.M., 2004. Functional interaction between Smad, CREB binding protein, and p68 RNA helicase. Biochem. Biophys. Res. Commun. 324: 70-76.

Jansson, M.D. and A. H. Lund. 2012. MicroRNA and cancer. Molecular Oncology 6: 590-610.

Laura, M.S. Seeber, A. Horrée, N.A. Marc, A.G.G. Vooijs, A. Peter, M. Heintz, Wall, E.V. D. René, H.M. Verheijen, P. J. and Diest, V. 2011. The role of hypoxia inducible factor-1alpha in gynecological cancer. Critical Rev in Oncol/Hematol. (78):173-184.

Semenza, G.L. 2010. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 20(1): 51.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.